Mesenteric Pulsatility Index Analysis Predicts Response to Azathioprine in Patients with Crohnʼs Disease

Nils Homann(Fraunhofer Project Centre Wolfsburg), D Ludwig, Eduard F. Stange(John Radcliffe Hospital), Ute Klarmann(Robert Bosch Hospital), Klaus Fellermann(Apple (Israel)), Thomas Witthöft(Robert Bosch Hospital), Rolf D. Klingenberg-Noftz(University Hospital Schleswig-Holstein), Andreas Brüning(University of Lübeck)

Inflammatory Bowel Diseases

January 30, 2005

10.1097/00054725-200502000-00005

Cited by 29

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Reduced Paneth cell α-defensins in ileal Crohn's disease

|Proceedings of the National Academy of Sciences|2005|969

NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression

|Gut|2004|798

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

|Journal of Clinical Oncology|2008|784

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738